Showing results (711-720 of 1,019) with videos related to

Sort By:
Pageof 102
Cytometry. Part B, Clinical Cytometry|August 23, 2024
The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cellsTom Reuvekamp, Luca L G Janssen, Lok Lam Ngai, et al.
Journal of Oncology Practice|May 2, 2012
Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer centerKim-Son H Nguyen, Rachel A Sanford, Mark S Huberman, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|June 10, 2006
Neuronal pentraxins mediate synaptic refinement in the developing visual systemLisa Bjartmar, Andrew D Huberman, Erik M Ullian, et al.
Cell|October 13, 2009
Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesisCagla Eroglu, Nicola J Allen, Michael W Susman, et al.
Cancer Discovery|September 12, 2015
NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK InhibitionMaria E R Garcia-Rendueles, Julio C Ricarte-Filho, Brian R Untch, et al.
Plos One|July 11, 2014
Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphomaJustin Rendleman, Yevgeniy Antipin, Boris Reva, et al.
Nature Genetics|September 22, 2014
PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumorsWilliam Lee, Sewit Teckie, Thomas Wiesner, et al.
JCO Precision Oncology|July 7, 2022
Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell CarcinomaRitesh R Kotecha, Erika Gedvilaite, Ryan Ptashkin, et al.
Hemasphere|December 29, 2021
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working PartyJesse M Tettero, Sylvie Freeman, Veit Buecklein, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 25, 2009
Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancerLecia V Sequist, Panos M Fidias, Jennifer S Temel, et al.
Pageof 102